Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Eficacia y Seguridad de un Nutracéutico Bebible para la Caída del Cabello en Pacientes que Utilizan Agonistas de los Receptores GLP-1/GIP

1 de octubre de 2026 actualizado por: Olistic Research Labs S.L.

Evaluación de la Eficacia y Seguridad de un Nutracéutico Bebible para Mejorar la Caída del Cabello en Pacientes Tratados con Agonistas del Receptor GLP-1/GIP: un Estudio Doble Ciego, Aleatorizado 1:1, Controlado con Placebo.

The purpose of this clinical trial is to evaluate the efficacy of Olistic© Next Women, a nutraceutical supplement, compared with placebo in improving hair loss in patients undergoing treatment with GLP-1/GIP agonists. This 6-month, randomized, placebo-controlled clinical study investigates whether daily supplementation with Olistic© Next Women leads to significant improvements in hair loss in this patient population. In addition, the study assesses the safety and tolerability of the product throughout the treatment period.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

40

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Madrid
      • Madrid, Madrid, España, 28006
        • Reclutamiento
        • Grupo Dermatologico Y Estetico Pedro Jaen S.A.
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

35 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Female gender.
  • Age >35 years.
  • Initiation of treatment with a GLP-1/GIP agonist, or treatment duration < 3 months, as per routine clinical practice in the endocrinology clinic.
  • Having signed the participant information sheet and the written informed consent and having been informed of the objective of the study.
  • Additional criteria to be included by the client.

Exclusion Criteria:

  • Allergy or hypersensitivity to any of the components of the product, or to a product from a similar category to the one being tested.
  • Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate to severe seborrheic dermatitis, eczema, cancer, etc.
  • Women presenting alopecia due to an underlying medical condition (hypothyroidism, anemia, lupus, etc.).
  • Pharmacological treatment that may promote the onset of telogen effluvium, initiated within the 3 months prior to study start (e.g., valproic acid, carbamazepine, phenytoin, selective serotonin reuptake inhibitors, oral anticoagulants, retinoids, beta-blockers). Patients who have undergone a dose change of these medications within the same period are also excluded.
  • Women with uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism) within the 6 months prior to study initiation.
  • Women who have used anti-hair loss products within the last 3 months.
  • Women who have initiated or undergone dermatological treatment for hair loss within the last 6 months (minoxidil, finasteride, PRP, mesotherapy, etc.).
  • Women who have undergone hair transplantation within the 18 months prior to study initiation.
  • Women who have initiated treatment with anxiolytics, antidepressants, amphetamines, ACE inhibitors, or iron within the last 3 months.
  • Women who initiated or discontinued hormonal treatment (oral contraceptives, oral or topical hormone replacement therapy, ovarian stimulation) within the 3 months prior to study initiation.
  • Pregnant women, postpartum women (within 6 months), breastfeeding women, or women planning to become pregnant during the study period.
  • Additional exclusion criteria to be specified by the sponsor.
  • Any condition that, in the investigator's opinion, makes participation in the study inappropriate.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: Brazo de placebo

Drinkable formulation consisting of an excipient formulation designed to mimic the organoleptic properties of the active product, reproducing its color and texture while achieving a highly similar taste profile.

Experimental: Brazo de Producto Activo

Drinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, amino acids, plant extracts, and other bioactive compounds designed to support hair growth and scalp health in women +45.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Hair loss
Periodo de tiempo: From baseline to Day 180.

• Patient Reported Outcome using the Hair Shedding Scale: will assess the degree of hair loss among participants. On the day of the visit, they will be shown an A4 sheet with six ranges: between 1 (minimal shedding) to 6 (copious hair shedding).

Ref. Perera E and Sinclair R, 2017

From baseline to Day 180.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Hair loss
Periodo de tiempo: From baseline to Day 180.

Comb and Wash Test: this test will quantify the number of fallen hairs (outcome number of shed hairs). It will be carried out after refraining from washing the hair for 48 hours and combing the hair for 24 hours.

From baseline to Day 180.
Body composition
Periodo de tiempo: From baseline to Day 180.

Body weight (Kg). Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor

From baseline to Day 180.
Body composition
Periodo de tiempo: From baseline to Day 180.

BMI (Kg/m2). Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor

From baseline to Day 180.
Body composition
Periodo de tiempo: From baseline to Day 180.

Fat mass and fat-free mass percentages. Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor

From baseline to Day 180.
Serum iron level
Periodo de tiempo: From baseline to Day 180.

Serum iron concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Ferritin level
Periodo de tiempo: From baseline to Day 180.

Serum ferritin concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Transferrin level
Periodo de tiempo: From baseline to Day 180.

Serum transferrin concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Transferrin saturation
Periodo de tiempo: From baseline to Day 180.

Transferrin saturation percentage calculated from iron metabolism parameters obtained from blood samples.

From baseline to Day 180.
Serum zinc level
Periodo de tiempo: From baseline to Day 180.

Serum zinc concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
25-hydroxyvitamin D level
Periodo de tiempo: From baseline to Day 180.

Serum 25-hydroxyvitamin D concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Serum folate level
Periodo de tiempo: From baseline to Day 180.

Serum folate concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Vitamin B12 level
Periodo de tiempo: From baseline to Day 180.

Serum vitamin B12 concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Serum albumin level
Periodo de tiempo: From baseline to Day 180.

Serum albumin concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Thyroid-stimulating hormone (TSH) level
Periodo de tiempo: From baseline to Day 180.

Serum thyroid-stimulating hormone concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Free thyroxine (free T4) level
Periodo de tiempo: From baseline to Day 180.

Serum free thyroxine concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Total testosterone level
Periodo de tiempo: From baseline to Day 180.

Serum total testosterone concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Free testosterone level
Periodo de tiempo: From baseline to Day 180.

Serum free testosterone concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Dehydroepiandrosterone sulfate (DHEA-S) level
Periodo de tiempo: From baseline to Day 180.

Serum dehydroepiandrosterone sulfate concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Sex hormone-binding globulin (SHBG) level
Periodo de tiempo: From baseline to Day 180.

Serum sex hormone-binding globulin concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Fasting glucose level
Periodo de tiempo: From baseline to Day 180.

Fasting blood glucose concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Glycated hemoglobin (HbA1c)
Periodo de tiempo: From baseline to Day 180.

Glycated hemoglobin measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Fasting insulin level
Periodo de tiempo: From baseline to Day 180.

Fasting serum insulin concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
HOMA-IR
Periodo de tiempo: From baseline to Day 180.

Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) calculated from fasting glucose and fasting insulin values.

From baseline to Day 180.
Total cholesterol level
Periodo de tiempo: From baseline to Day 180.

Total cholesterol concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
HDL cholesterol level
Periodo de tiempo: From baseline to Day 180.

HDL cholesterol concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
LDL cholesterol level
Periodo de tiempo: From baseline to Day 180.

LDL cholesterol concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Triglyceride level
Periodo de tiempo: From baseline to Day 180.

Serum triglyceride concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Aspartate aminotransferase (AST) level
Periodo de tiempo: From baseline to Day 180.

AST concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Alanine aminotransferase (ALT) level
Periodo de tiempo: From baseline to Day 180.

ALT concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Gamma-glutamyl transferase (GGT) level
Periodo de tiempo: From baseline to Day 180.

GGT concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Blood urea level
Periodo de tiempo: From baseline to Day 180.

Blood urea concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Serum creatinine level
Periodo de tiempo: From baseline to Day 180.

Serum creatinine concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Self-assessment questionnaire
Periodo de tiempo: From baseline to Day 180.

Subject-reported perception of hair condition assessed using a 12-item questionnaire covering perceived hair density, hair shedding, hair strength, hair volume, appearance, and scalp condition. Each item is rated on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree." Higher scores indicate greater perceived improvement in hair and scalp condition.

From baseline to Day 180.
Food consumption frequency questionnaire (PREDIMED questionnaire)
Periodo de tiempo: From baseline to Day 180.

Adherence to the Mediterranean diet assessed using the validated 14-item PREDIMED (Prevención con Dieta Mediterránea) questionnaire. The questionnaire evaluates the frequency of consumption of key food groups and dietary habits characteristic of the Mediterranean diet, including olive oil use, fruit and vegetable intake, legumes, fish, nuts, red meat, sugary beverages, commercial pastries, and wine consumption. Each item is scored 0 or 1, resulting in a total score ranging from 0 to 14, with higher scores indicating greater adherence to the Mediterranean diet.

From baseline to Day 180.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

16 de marzo de 2026

Finalización primaria (Estimado)

31 de mayo de 2027

Finalización del estudio (Estimado)

31 de agosto de 2027

Fechas de registro del estudio

Enviado por primera vez

9 de marzo de 2026

Primero enviado que cumplió con los criterios de control de calidad

17 de marzo de 2026

Publicado por primera vez (Actual)

19 de marzo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

1 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CT-ON-04

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .